Bridget E. Bunner

Array ( [id] => 10298857 [patent_doc_number] => 20150183856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-02 [patent_title] => 'Novel Monoclonal Antibody Binding Specifically to DLL4 and Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/412419 [patent_app_country] => US [patent_app_date] => 2013-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11653 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14412419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134403 [patent_doc_number] => 20130295117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'ALDOSTERONE INDUCED ELASTIN PRODUCTION' [patent_app_type] => utility [patent_app_number] => 13/924502 [patent_app_country] => US [patent_app_date] => 2013-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9337 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13924502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9262159 [patent_doc_number] => 20130344088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-26 [patent_title] => 'ANTIBODY FORMULATION' [patent_app_type] => utility [patent_app_number] => 13/912355 [patent_app_country] => US [patent_app_date] => 2013-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19658 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13912355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9427628 [patent_doc_number] => 08703702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-22 [patent_title] => 'Therapeutically active α-MSH analogues' [patent_app_type] => utility [patent_app_number] => 13/908636 [patent_app_country] => US [patent_app_date] => 2013-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25538 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13908636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10255003 [patent_doc_number] => 20150140000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'TLR3 BINDING AGENTS' [patent_app_type] => utility [patent_app_number] => 14/403171 [patent_app_country] => US [patent_app_date] => 2013-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 39025 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14403171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10566337 [patent_doc_number] => 09289489 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-22 [patent_title] => 'NOTCH inhibition in the treatment of cardiovascular disease' [patent_app_type] => utility [patent_app_number] => 13/903288 [patent_app_country] => US [patent_app_date] => 2013-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8064 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13903288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10374402 [patent_doc_number] => 20150259409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'ANTI-BLYS ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/401288 [patent_app_country] => US [patent_app_date] => 2013-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8419 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14401288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9263204 [patent_doc_number] => 20130345133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-26 [patent_title] => 'Adiponectin for Treating Pulmonary Disease' [patent_app_type] => utility [patent_app_number] => 13/896279 [patent_app_country] => US [patent_app_date] => 2013-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9384 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9162040 [patent_doc_number] => 20130310317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-21 [patent_title] => 'TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR' [patent_app_type] => utility [patent_app_number] => 13/892418 [patent_app_country] => US [patent_app_date] => 2013-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 47027 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13892418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147747 [patent_doc_number] => 20130302270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'TUMOR TARGETED TNF-RELATED APOPTOSIS INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/892238 [patent_app_country] => US [patent_app_date] => 2013-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9953 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13892238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10897893 [patent_doc_number] => 08921106 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-30 [patent_title] => 'Antibodies that bind the glutamate ligand binding region of NOTCH3' [patent_app_type] => utility [patent_app_number] => 13/890805 [patent_app_country] => US [patent_app_date] => 2013-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 23 [patent_no_of_words] => 31240 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13890805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10255046 [patent_doc_number] => 20150140043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'IMMUNOMODULATORY METHODS USING NOTCH AGONISTS' [patent_app_type] => utility [patent_app_number] => 14/399977 [patent_app_country] => US [patent_app_date] => 2013-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9997 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14399977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9222476 [patent_doc_number] => 20140017250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-16 [patent_title] => 'Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases' [patent_app_type] => utility [patent_app_number] => 13/887797 [patent_app_country] => US [patent_app_date] => 2013-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 35779 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13887797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9121451 [patent_doc_number] => 20130288374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS' [patent_app_type] => utility [patent_app_number] => 13/862087 [patent_app_country] => US [patent_app_date] => 2013-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 7117 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13862087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173929 [patent_doc_number] => 20130315914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'Anti-TLR4 Antibodies and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 13/853158 [patent_app_country] => US [patent_app_date] => 2013-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 33223 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13853158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12192778 [patent_doc_number] => 09896497 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-20 [patent_title] => 'Toll-like receptor 2 binding epitope and binding member thereto' [patent_app_type] => utility [patent_app_number] => 14/384824 [patent_app_country] => US [patent_app_date] => 2013-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 22494 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14384824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8990347 [patent_doc_number] => 20130217628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'Therapeutically Active Alpha-MSH Analogues' [patent_app_type] => utility [patent_app_number] => 13/847275 [patent_app_country] => US [patent_app_date] => 2013-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25493 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13847275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8940438 [patent_doc_number] => 20130190235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-25 [patent_title] => 'FUSION PROTEIN FOR ANTAGONIZING ANGIOGENESIS INDUCIBLE FACTORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/842667 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 19854 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13842667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9107145 [patent_doc_number] => 20130280277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-24 [patent_title] => 'NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/826284 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 33313 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13826284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9922303 [patent_doc_number] => 08980260 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-17 [patent_title] => 'Monoclonal antibody that binds human notch2 and notch3' [patent_app_type] => utility [patent_app_number] => 13/826432 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 50 [patent_no_of_words] => 53609 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13826432 [rel_patent_id] =>[rel_patent_doc_number] =>)